2 weeks Ago By ABMN Staff
LPL Financial LLC grew its holdings in shares of Cytokinetics, Incorporated ( NASDAQ:CYTK – Free Report ) by 6.6% during the fourth quarter, Holdings Channel.com reports.
The institutional investor owned 13,988 shares of the biopharmaceutical company’s stock after purchasing an additional 870 shares during the quarter. LPL Financial LLC’s holdings in Cytokinetics were worth $658,000 at the end of the most recent quarter. Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock.
Retirement Systems of Alabama lifted its holdings in shares of Cytokinetics by 1.0% in the third quarter. Retirement Systems of Alabama now owns 142,930 shares of the biopharmaceutical company’s stock valued at $7,547,000 after purchasing an additional 1,414 shares in the last quarter.
Exome Asset Management LLC bought a new stake in shares of Cytokinetics in the third quarter valued at $3,093,000. Harbor Capital Advisors Inc. grew its stake in shares of Cytokinetics by 6.
1% during the 4th quarter. Harbor Capital Advisors Inc. now owns 45,130 shares of the biopharmaceutical company’s stock worth $2,123,000 after acquiring an additional 2,604 shares during the period.
Mirador Capital Partners LP increased its holdings in Cytokinetics by 1.6% in the 4th quarter. Mirador Capital Partners LP now owns 65,636 shares of the biopharmaceutical company’s stock worth $3,088,000 after acquiring an additional 1,010 shares during the last quarter.
Finally, Inspire Investing LLC increased its holdings in Cytokinetics by 7.8% in the 4th quarter. Inspire Investing LLC now owns 8,504 shares of the biopharmaceutical company’s stock worth $400,000 after acquiring an additional 616 shares during the last quarter.
Analyst Upgrades and Downgrades A number of equities analysts have weighed in on CYTK shares. Bank of America cut their target price on shares of Cytokinetics from $62.00 to $54.
00 and set a “neutral” rating for the company in a research report on Tuesday, April 15th. JMP Securities reiterated a “market outperform” rating and issued a $78.00 price objective on shares of Cytokinetics in a research note on Thursday, April 10th.
Stifel Nicolaus assumed coverage on shares of Cytokinetics in a report on Wednesday, January 22nd. They set a “buy” rating and a $80.00 target price on the stock.
HC Wainwright reaffirmed a “buy” rating and issued a $120.00 price target on shares of Cytokinetics in a report on Monday. Finally, Morgan Stanley set a $67.
00 price objective on Cytokinetics in a research note on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Cytokinetics has a consensus rating of “Moderate Buy” and an average target price of $81.
63. Cytokinetics Stock Performance Shares of CYTK opened at $38.00 on Thursday.
Cytokinetics, Incorporated has a 12-month low of $32.74 and a 12-month high of $68.44.
The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.
93. The company has a market cap of $4.53 billion, a PE ratio of -7.
06 and a beta of 0.94. The stock has a 50-day moving average price of $42.
31 and a 200-day moving average price of $47.40. Cytokinetics ( NASDAQ:CYTK – Get Free Report ) last announced its earnings results on Thursday, February 27th.
The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.
03. The company had revenue of $16.93 million for the quarter, compared to the consensus estimate of $14.
26 million. As a group, equities analysts forecast that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.
Insider Transactions at Cytokinetics In related news, CEO Robert I. Blum sold 16,970 shares of the firm’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $43.
44, for a total transaction of $737,176.80. Following the transaction, the chief executive officer now directly owns 364,181 shares of the company’s stock, valued at approximately $15,820,022.
64. This trade represents a 4.45 % decrease in their position.
The sale was disclosed in a filing with the SEC, which is accessible through this link . Also, Director Wendall Wierenga sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $38.
46, for a total value of $769,200.00. Following the completion of the sale, the director now directly owns 24,848 shares of the company’s stock, valued at approximately $955,654.
08. This represents a 44.60 % decrease in their position.
The disclosure for this sale can be found here . In the last ninety days, insiders sold 88,360 shares of company stock valued at $3,643,645. Insiders own 3.
40% of the company’s stock. Cytokinetics Company Profile ( Free Report ) Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
Recommended Stories Want to see what other hedge funds are holding CYTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytokinetics, Incorporated ( NASDAQ:CYTK – Free Report ). Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.
com's FREE daily email newsletter ..
